In July, Seeking Alpha welcomed 44 new analysts. This article introduces them and showcases some of their top picks. Analysts ...

AstraZeneca, which last week announced a $50bn plan for US development, declined to comment. Pfizer, Abbvie, and Germany’s ...

Research and development expenses fell 48.2% compared to Q2 2024, while general and administrative costs rose 121.1%, Research and development expenses were $1.0 million compared to $2.1 million for ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Pfizer, with a price target of $30.00. The company’s shares closed yesterday at $23.53. Take advantage of TipRanks ...